|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Mistral Pharma Inc. Announces its Financial Results for the Second Quarter Ended September 30, 2007
11/26/2007 4:08:37 PM
MONTREAL, QUEBEC--(Marketwire - November 23, 2007) - Mistral Pharma Inc. (TSX VENTURE: MIP) (the "Corporation", "Mistral") announces today its financial results and review of operating highlights for the second quarter and for the six-month period ended September 30, 2007. "The highlights of Mistral's second quarter were the successful pilot clinical trial of our MIST-B03 product, the signing of a method use license for our MIST-B02 product and of course, the preparation for the launch of the recently approved Instillagel® by Health Canada ", said Bertrand Bolduc, the Corporation's President & CEO. "As planned, we had a successful product launch at the beginning of November 2007 "he added.
|
|
|
|
|
|
|
|
|
|
|